Galena Biopharma Settles Opioid Kickback Allegations
By Michael Mezher -
Published 08 September 2017
Galena Biopharma has agreed to pay more than $7 million to settle allegations made in a whistleblower suit that the company gave kickbacks to doctors to boost prescriptions for the company's sublingual fentanyl drug Abstral.
Categories: News, US, DOJ, FDA, Advertising and Promotion, Drugs
Tags: Abstral, Galena
FDA, DOJ Investigate Galena Biopharma’s Former Promotions of Fentanyl
By Zachary Brennan -
Published 09 January 2017
Galena Biopharma on Monday disclosed in an SEC filing that the US Attorney’s Office for the District of New Jersey and the US Department of Justice (DOJ) are pursuing a criminal investigation, in addition to a previously announced civil investigation, related to the marketing and promotion of its deadly opioid Abstral (fentanyl), which the company sold for $8 million upfront in 2015.
Categories: News, US, DOJ, FDA, Advertising and Promotion, Drugs, Regulatory intelligence
Tags: Galena, DOJ, Abstral, fentanyl marketing